| Name | Imiquimod maleate |
| Description | Imiquimod maleate (R 837 maleate) is a toll-like receptor 7 (TLR7) agonist and immune response modifier with antiviral and antitumor activities. It is used in the study of external genital warts, perianal warts, cancer, and COVID-19, and can induce psoriasis-like skin lesions in mice, commonly used to establish psoriasis models. |
| In vivo | In animal models, Imiquimod maleate stimulates the innate immune response by increasing NK cell activity, activating macrophages to secrete cytokines and nitric oxide, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α, and inducing proliferation and differentiation of B lymphocytes. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 1 mg/mL (2.81 mM), Sonication is recommended.
DMSO : 20 mg/mL (56.12 mM), Sonication is recommended.
|
| Keywords | Toll-like Receptor (TLR) | SARS-CoV | SARSCoV | HSV | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
